Autobio Diagnostics Co Ltd
SSE:603658

Watchlist Manager
Autobio Diagnostics Co Ltd Logo
Autobio Diagnostics Co Ltd
SSE:603658
Watchlist
Price: 41.25 CNY -1.08% Market Closed
Market Cap: 24B CNY
Have any thoughts about
Autobio Diagnostics Co Ltd?
Write Note

Net Margin
Autobio Diagnostics Co Ltd

27.8%
Current
27%
Average
2.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
27.8%
=
Net Income
1.3B
/
Revenue
4.6B

Net Margin Across Competitors

Country CN
Market Cap 24B CNY
Net Margin
28%
Country JP
Market Cap 7T JPY
Net Margin
24%
Country CH
Market Cap 37.8B CHF
Net Margin
12%
Country DK
Market Cap 178.8B DKK
Net Margin
19%
Country US
Market Cap 16.1B USD
Net Margin
11%
Country KR
Market Cap 10.5T KRW
Net Margin
-358%
Country CN
Market Cap 51.1B CNY
Net Margin
42%
Country US
Market Cap 6.5B USD
Net Margin
29%
Country CA
Market Cap 6.4B USD
Net Margin
-8%
Country US
Market Cap 5.7B USD
Net Margin
9%
Country UK
Market Cap 4.6B GBP
Net Margin
7%
No Stocks Found

Autobio Diagnostics Co Ltd
Glance View

Market Cap
24B CNY
Industry
Health Care

Autobio Diagnostics Co., Ltd. is a company that has carved a distinctive niche in the biotechnology landscape, particularly within the realm of in-vitro diagnostics (IVD). The company's journey began with a mission to enhance healthcare by providing advanced diagnostic tools that offer precise and timely results. Specializing in the development, production, and distribution of diagnostic reagents and instruments, Autobio has dedicated itself to innovation and quality in medical diagnostics. Its expansive product portfolio covers areas such as immunoassay detection, microbiology, clinical chemistry, and molecular diagnostics, catering to both hospital laboratories and independent labs. The firm prides itself on adopting cutting-edge technology to create solutions that are not only efficient and cost-effective but also align with global health standards. The financial heartbeat of Autobio lies in its strategic approach to generating revenue through diverse streams. With a keen focus on research and development, the company continually innovates its product lines, thereby sustaining a competitive edge in the fast-evolving diagnostics market. Additionally, its revenue model capitalizes heavily on the consumables-market; reagents and test kits are used in routine diagnostics, creating a recurring income source as these products need constant replenishment. By expanding its geographic footprint through partnerships and direct sales channels, Autobio enhances its market reach, strengthening its ability to leverage scale economies. Moreover, the company’s commitment to maintaining strong customer relationships through robust after-sales service and technical support has built a loyal base, further fueling its revenue engine.

Intrinsic Value
75.56 CNY
Undervaluation 45%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
27.8%
=
Net Income
1.3B
/
Revenue
4.6B
What is the Net Margin of Autobio Diagnostics Co Ltd?

Based on Autobio Diagnostics Co Ltd's most recent financial statements, the company has Net Margin of 27.8%.